FDA Expands Repatha's Use to Strengthen Protection Against Heart Disease

The U.S. Food and Drug Administration (FDA) widened its approval of Repatha in August, offering stronger protection against heart disease. This move follows research showing the drug's effectiveness in cutting heart attack and stroke risks. Cardiovascular conditions remain the world's top killers, making treatments like Repatha increasingly important.

Repatha, developed by Amgen, contains the active ingredient evolocumab. When paired with statins or other LDL-lowering treatments, it reduced heart attack risk by 36% in high-risk patients. Studies also found a 25% drop in serious cardiovascular events for those with no prior history of heart attack or stroke.

Patients on evolocumab achieved a median LDL cholesterol level of 45 mg/dL, far below the placebo group's 109 mg/dL. High LDL cholesterol contributes to artery-clogging plaque, a major cause of heart attacks. Amgen's research chief, Jay Bradner, highlighted that Repatha helps prevent heart attacks and strokes before they even occur.

The drug has been available in Germany since 2015 for certain types of hypercholesterolemia in adults. In late 2021, its approval extended to children and adolescents with heterozygous familial hypercholesterolemia.

The FDA's expanded approval strengthens Repatha's role in preventing cardiovascular disease. With proven results in lowering LDL cholesterol and reducing heart attack risks, the drug offers a key option for high-risk patients. Further details on cost and availability in the U.S. compared to other therapies remain unclear.